Loss of CADM1 expression by promoter hypermethylation or loss of heterozygosity (LOH) has been strongly linked to poor prognosis, tumour progression, invasion and metastasis in many cancers, and has thus become an attractive diagnostic and prognostic biomarker [69]. This evidence concerns the gene CADM1 and cancer.